CN105796507B - 含聚乙二醇化门冬酰胺酶的药物组合物及其制备方法 - Google Patents
含聚乙二醇化门冬酰胺酶的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN105796507B CN105796507B CN201410837626.8A CN201410837626A CN105796507B CN 105796507 B CN105796507 B CN 105796507B CN 201410837626 A CN201410837626 A CN 201410837626A CN 105796507 B CN105796507 B CN 105796507B
- Authority
- CN
- China
- Prior art keywords
- pegaspargase
- pharmaceutical composition
- mass percentage
- sample
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010001564 pegaspargase Proteins 0.000 title claims abstract description 174
- 229960001744 pegaspargase Drugs 0.000 title claims abstract description 131
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 title claims abstract description 130
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title description 85
- 239000000872 buffer Substances 0.000 claims abstract description 30
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 11
- 239000010452 phosphate Substances 0.000 claims abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 9
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 8
- 229930195725 Mannitol Natural products 0.000 claims abstract description 8
- 239000008101 lactose Substances 0.000 claims abstract description 8
- 239000000594 mannitol Substances 0.000 claims abstract description 8
- 235000010355 mannitol Nutrition 0.000 claims abstract description 8
- 239000003223 protective agent Substances 0.000 claims abstract description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 6
- 229930006000 Sucrose Natural products 0.000 claims abstract description 6
- 239000005720 sucrose Substances 0.000 claims abstract description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims abstract description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 104
- 238000004108 freeze drying Methods 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 34
- 239000002202 Polyethylene glycol Substances 0.000 claims description 30
- 238000002347 injection Methods 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 6
- 230000006320 pegylation Effects 0.000 claims description 6
- 108700023418 Amidases Proteins 0.000 claims description 5
- 102000005922 amidase Human genes 0.000 claims description 5
- 108010024976 Asparaginase Proteins 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 abstract description 17
- 238000006731 degradation reaction Methods 0.000 abstract description 17
- 238000007710 freezing Methods 0.000 abstract description 5
- 230000008014 freezing Effects 0.000 abstract description 5
- 239000000523 sample Substances 0.000 description 99
- 229940099216 oncaspar Drugs 0.000 description 43
- 239000000243 solution Substances 0.000 description 37
- 230000000694 effects Effects 0.000 description 34
- 230000004048 modification Effects 0.000 description 29
- 238000012986 modification Methods 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- 229940090044 injection Drugs 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 230000008859 change Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000001962 electrophoresis Methods 0.000 description 11
- 230000002255 enzymatic effect Effects 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000008363 phosphate buffer Substances 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- 238000010257 thawing Methods 0.000 description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- 229960001230 asparagine Drugs 0.000 description 8
- 235000009582 asparagine Nutrition 0.000 description 8
- 238000005192 partition Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 229920001427 mPEG Polymers 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000001952 enzyme assay Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 230000003028 elevating effect Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000005496 eutectics Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000000859 sublimation Methods 0.000 description 4
- 230000008022 sublimation Effects 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- -1 acyl Amine Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- DTQADTCKBSDHSU-UHFFFAOYSA-L potassium mercury(1+) diiodide Chemical compound [Hg+].[I-].[K+].[I-] DTQADTCKBSDHSU-UHFFFAOYSA-L 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DYMYLBQTHCJHOQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) butanoate Chemical compound CCCC(=O)ON1C(=O)CCC1=O DYMYLBQTHCJHOQ-UHFFFAOYSA-N 0.000 description 1
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- MRMOMIYVTPUCMS-UHFFFAOYSA-N acetic acid;pyrrolidine-2,5-dione Chemical class CC(O)=O.O=C1CCC(=O)N1 MRMOMIYVTPUCMS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 229940066058 pegaspargase injection Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Abstract
Description
制备例 | 缓冲体系 | 辅料1 | 辅料2 | 聚乙二醇化门冬酰胺酶 |
制备例4 | 25%Tris-Hcl(PH8.0) | 30%山梨醇 | 40%甘露醇 | 5% |
制备例5 | 10%Tris-Hcl(PH8.0) | 20%山梨醇 | 60%蔗糖 | 10% |
制备例6 | 8%磷酸盐(PH7.0) | 31.5%山梨醇 | 0.5%吐温80 | 60% |
制备例7 | 15%磷酸盐(PH7.0) | 20%山梨醇 | 45%乳糖 | 20% |
制备例8 | 20%磷酸盐(PH7.0) | 60%山梨醇 | 2%吐温80 | 18% |
制备例 | 缓冲体系 | 辅料1 | 辅料2 | 聚乙二醇化门冬酰胺酶 |
制备例4 | 8%Tris-Hcl(PH8.0) | 20%甘露醇 | 67%蔗糖 | 5% |
制备例5 | 5%Tris-Hcl(PH8.0) | 15%甘露醇 | 70%乳糖 | 10% |
制备例6 | 10%磷酸盐(PH7.0) | 49.5%海藻糖 | 0.5%吐温80 | 40% |
制备例7 | 15%磷酸盐(PH7.0) | 60%乳糖 | 5%吐温80 | 20% |
制备例8 | 30%磷酸盐(PH7.0) | 30%乳糖 | 22%蔗糖 | 18% |
样品来源 | 冻干前(IU) | 冻干后(IU) | 酶活性变化(%) |
实施例1制备例1 | 151 | 153 | 1.3% |
实施例1制备例2 | 150 | 138 | -8% |
实施例1制备例3 | 153 | 139 | -9.2% |
实施例2制备例1 | 151 | 78 | -48.3% |
实施例2制备例2 | 158 | 114 | -27.8% |
实施例2制备例3 | 154 | 101 | -34.4% |
样品来源 | 0个月 | 加速2个月 | 酶活性变化 |
实施例1制备例1 | 153 | 150 | 2% |
培门冬酶 | 150 | 0 | 100% |
样品来源 | 0个月 | 高温2个月 | 酶活性变化 |
实施例1制备例1 | 155 | 150 | 2% |
培门冬酶 | 149 | 0 | 100% |
样品 | 平均修饰度 | 偶联的PEG个数 |
Oncaspar | 65.6% | 21.64 |
SPA5K-ASP | 65% | 21.45 |
培门冬酶 | 57.4% | 18.942 |
肿瘤细胞 | Oncaspar | SPA5K-ASP | 培门冬酶 |
THP-1 | 7.5μmol/L | 3.05μmol/L | 7.9μmol/L |
Raji | 8.1μmol/L | 2.4μmol/L | 8.8μmol/L |
L1210 | 10.69μmol/L | 7.305μmol/L | 10.28μmol/L |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410837626.8A CN105796507B (zh) | 2014-12-29 | 2014-12-29 | 含聚乙二醇化门冬酰胺酶的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410837626.8A CN105796507B (zh) | 2014-12-29 | 2014-12-29 | 含聚乙二醇化门冬酰胺酶的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105796507A CN105796507A (zh) | 2016-07-27 |
CN105796507B true CN105796507B (zh) | 2019-01-18 |
Family
ID=56980839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410837626.8A Active CN105796507B (zh) | 2014-12-29 | 2014-12-29 | 含聚乙二醇化门冬酰胺酶的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105796507B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110195050B (zh) * | 2018-02-27 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | 一种高纯度门冬酰胺酶的制备方法 |
PE20220492A1 (es) * | 2018-12-24 | 2022-04-07 | Gennova Biopharmaceuticals Ltd | Composicion liofilizada de pegaspargasa |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2441914C1 (ru) * | 2010-10-06 | 2012-02-10 | Учреждение Российской академии медицинских наук Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича РАМН (ИБМХ РАМН) | Способ получения субстанции рекомбинантной l-аспарагиназы erwinia carotovora |
CN104046600A (zh) * | 2013-12-30 | 2014-09-17 | 江苏众红生物工程创药研究院有限公司 | 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用 |
-
2014
- 2014-12-29 CN CN201410837626.8A patent/CN105796507B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2441914C1 (ru) * | 2010-10-06 | 2012-02-10 | Учреждение Российской академии медицинских наук Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича РАМН (ИБМХ РАМН) | Способ получения субстанции рекомбинантной l-аспарагиназы erwinia carotovora |
CN104046600A (zh) * | 2013-12-30 | 2014-09-17 | 江苏众红生物工程创药研究院有限公司 | 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用 |
Non-Patent Citations (1)
Title |
---|
重组L-天冬酰胺酶制剂稳定性研究;王弘等;《药物生物技术》;19971231;第4卷(第2期);第93-97页 |
Also Published As
Publication number | Publication date |
---|---|
CN105796507A (zh) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2339402C2 (ru) | Лиофилизированный препарат, содержащий антитела против рецептора egf | |
EP2784093B1 (en) | Polyethylene glycol-modified integrin blocker hm-3 and use thereof | |
ES2435462T3 (es) | Formulación de proteína liofilizada isotónica estable | |
JP6961061B2 (ja) | 癌治療のためのadi−peg20抗体に対する交差反応性が低減したアルギニンデイミナーゼ | |
US20180207278A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
EP3932426A2 (en) | Preparations containing anti-cd47 antibody, and preparation method and use therefor | |
CA2668947A1 (en) | Liquid anti-rabies antibody formulations | |
CN105796507B (zh) | 含聚乙二醇化门冬酰胺酶的药物组合物及其制备方法 | |
CN105802948A (zh) | 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用 | |
CN107760661B (zh) | 药用激肽原酶的peg修饰物及其制备方法和应用 | |
JP2023085555A (ja) | 抗Her2抗体薬物コンジュゲートの製剤 | |
CN108379561A (zh) | 一种聚乙二醇化尿酸氧化酶冻干粉剂及其制备方法 | |
CN113769081A (zh) | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 | |
EP4094777A1 (en) | Recombinant fully human anti-tigit monoclonal antibody preparations, preparation method therefor and use thereof | |
EP4368251A2 (en) | Therapeutic conjugate | |
CN107753953B (zh) | 聚乙二醇化激肽原酶的制剂及其应用 | |
JP2023523218A (ja) | ヘテロ二量体ヒトインターロイキン-15(hetIL-15)の医薬組成物及び医薬製品 | |
CN109535247A (zh) | 聚乙二醇修饰的藻蓝蛋白及其制备方法与制药应用 | |
Liu et al. | In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated antitumor polypeptide | |
CN110121340B (zh) | 聚乙二醇化精氨酸脱亚氨酶的调配物 | |
CN105802946A (zh) | 聚乙二醇化的门冬酰胺酶及其应用 | |
CN111346220A (zh) | 一种聚乙二醇修饰的血管内皮抑制素制剂组合物 | |
CN102327242B (zh) | 一种聚乙二醇-集成干扰素变异体冻干制剂 | |
CN107693796A (zh) | Peg定点修饰的门冬酰胺酶注射剂 | |
CN114246944A (zh) | 一种双特异性抗体的药物组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Applicant after: ZonHon Biopharma Institute Inc. Applicant after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Address before: 213022 the Yellow River Middle Road, Xinbei District, Jiangsu, China, No. 132, No. Applicant before: ZonHon Biopharma Institute Inc. Applicant before: Changzhou Gensun Institute of Biomedicine Co., Ltd. |
|
COR | Change of bibliographic data | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 213125, Yunhe Road, Xinbei District, Jiangsu, Changzhou, 518 Applicant after: ZonHon Biopharma Institute Inc. Applicant after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Address before: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Applicant before: ZonHon Biopharma Institute Inc. Applicant before: Changzhou Gensun Institute of Biomedicine Co., Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee after: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190712 Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
TR01 | Transfer of patent right |